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Background and objectives: Chronic kidney disease is associated with a higher risk of cardiovascular outcomes. The
prognostic significance of worsening renal function has also been shown in various cohorts of cardiac disease; however, the
predictors of worsening renal function and the contribution of inflammation remains to be established.
Design, setting, participants, & measurements: Worsening renal function was defined as a 25% or more decrease in
estimated GFR (eGFR) over a 1-mo period in patients after a non-ST or ST elevation acute coronary syndromes participating
in the Aggrastat-to-Zocor Trial; this occurred in 5% of the 3795 participants.
Results: A baseline C-reactive protein (CRP) in the fourth quartile was a significant predictor of developing worsening renal
function (odds ratio, 2.48; 95% confidence interval, 1.49, 4.14). After adjusting for baseline CRP and eGFR, worsening renal
function remained a strong multivariate predictor for the combined cardiovascular composite of CV death, recurrent myo-
cardial infarction (MI), heart failure or stroke (hazard ratio, 1.6; 95% confidence interval, 1.1, 2.3).
Conclusions: Patients with an early decline in renal function after an acute coronary syndrome are at a significant increased
risk for recurrent cardiovascular events. CRP is an independent predictor for subsequent decline in renal function and
reinforces the idea that inflammation may be related to the pathophysiology of progressive renal disease.
Clin J Am Soc Nephrol 4: 1811–1817, 2009. doi: 10.2215/CJN.03510509
I mpaired renal function has consistently been shown to bean independent risk factor for cardiovascular outcomesacross a broad spectrum of patients including population-
based studies of patients with cardiovascular disease (1,2),
acute coronary syndromes (3–6), chronic heart failure with
either impaired or preserved ventricular systolic function (7),
and after coronary artery bypass grafting (8). Worsening renal
function (WRF), defined by small increases in creatinine or
decreases in GFR, has also been independently associated with
adverse cardiovascular outcomes and mortality in patients after
an acute MI (9), cardiac surgery (10,11), and in patients with
heart failure (12–14).
Serum C-reactive protein (CRP), a marker of inflammation,
has been associated with WRF in a population of nondiabetics
(15), as well as in those after an MI (15,16). The predictors and
prognostic significance of WRF in a cohort of patients after an
acute coronary syndrome (ACS) is not well defined. Further-
more, the contribution of inflammatory markers to WRF in this
cohort is unknown. We analyzed subjects from the phase Z of
the A-Z trial (Early Intensive versus Delayed Conservative Sim-
vastatin Strategy in Patients with Acute Coronary Syndromes),
who had both measurements of serum creatinine and thus
estimates of GFR (eGFR), at baseline and 1 mo. We have pre-
viously reported that both baseline CRP and eGFR were im-
portant prognostic markers after an ACS and that the increased
cardiovascular hazard associated with a reduction in eGFR was
independent and additive to baseline markers of inflammation
(6). The objectives of this subsequent analysis was to determine
clinical factors associated with an early decline in eGFR after an
ACS and second to evaluate the cardiovascular prognostic im-
portance of an early decline in eGFR in this patient population.
Materials and Methods
Subjects
Patients studied were from phase Z of the Aggrastat to Zocor (A to
Z) trial, a multicenter randomized double blind trial evaluating an early
intensive simvastatin (simvastatin 40 mg/daily for 1 mo followed by 80
mg/daily) compared with delayed and less intensive simvastatin strat-
egy (placebo for 4 mo followed by simvastatin 20 mg/daily) in patients
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stabilized after a high-risk ACS event (17). Patients were excluded from
this trial if the index serum creatinine was2.0 mg/dl (178 mol/L) or
total cholesterol 250 mg/dl (6.48 mmol/L). (Serum creatinine in
mg/dl may be converted to mol/L by multiplying by 88.4.) Over the
trial duration of 6 to 24 mo, there was a nonsignificant trend toward a
reduction in the primary endpoint of cardiovascular death, MI, and
readmission for an ACS in favor of the intensive statin regimen (18).
There were a total of 4497 patients randomized to this trial with 4181
having measurements of both serum creatinine and CRP a mean of
4.6 d from symptom onset (median, 5 d; minimum, 2 d; maximum, 8 d).
Of the 4181 subjects, 3795 had repeat measurements of serum creatinine
at a mean of 32 d from the baseline measurement and were included in
this analysis (median, 32 d; minimum, 22 d; maximum, 55 d).
Estimation of Renal Function
Renal impairment was assessed by an estimation of GFR using the
Modification of Diet in Renal Disease equation. This is a four-compo-
nent equation incorporating age, race, sex, and serum creatinine level
by the following formula: estimated GFR  186  (serum creatinine
level in mg/dl)1.154  (age in years)0.203. The product of this formula
is multiplied by a correction factor of 0.742 for women and 1.21 for
African Americans (19).
For this analysis, worsening renal function was defined as a decrease
in eGFR of  25% compared with baseline. In sensitivity analyses, we
also reanalyzed the data defining worsening renal function as an ab-
solute increase in serum creatinine 0.3 mg/dl (20).
Statistical Analysis
Baseline characteristics between groups were compared with t tests
or Wilcoxon rank sum tests for normally or non-normally distributed
continuous variables, respectively. 2 tests were used for categorical
variables. Because CRP levels were non-normally distributed and
showed a nonlinear relationship to clinical outcomes, CRP was catego-
rized into quartiles for all analyses. Logistic regression was used to
identify univariate and multivariate predictors of a decrease of eGFR
25%. Covariates in these final models included age, male sex, CRP
quartile, baseline eGFR as a continuous variable, total cholesterol,
triglycerides, low-density lipoprotein (LDL), history of hypertension,
peripheral vascular disease, diabetes, current smoking, previous MI,
left ventricular (LV) dysfunction, index diagnosis, catheterization or
percutaneous intervention (PCI) for index event, treatment randomiza-
tion, history of diuretic use within 7 d of admission, new or increase in
diuretics in the first 30 d, angiotensin converting enzyme (ACE) inhib-
itor use at discharge, and new ACE inhibitor use in first 30 d.
Combined cardiovascular event-free survival (freedom from cardio-
vascular death, recurrent MI, heart failure, or stroke) was shown with
Kaplan-Meier curves and outcomes were compared with the log-rank
test. Independent predictors of the cardiovascular clinical events were
calculated using Cox proportional hazards modeling. All covariates
that were significant in the univariate analyses and those with impor-
tant clinical significance or confounding were entered into the final
model. Covariates in the final model included presence of WRF, base-
line eGFR, age, CRP quartiles, total cholesterol, triglycerides, LDL, sex,
race, history of hypertension, history of diabetes, smoking, previous
MI, LV dysfunction, index PCI, and treatment randomization.
All P values were two-sided and a P value of 0.05 was considered
statistically significant. All statistical analyses were performed using
STATA software, version 9.2 (Stata Corp., College Station, TX).
The authors had full access to the data and take responsibility for its
integrity. All authors have read and agree to the manuscript as written.
Outcomes
The primary outcome for these analyses was a composite of cardio-
vascular endpoints including cardiovascular death, hospitalization for
heart failure, recurrent MI, and stroke. With the exception of heart
failure endpoints, all events were adjudicated by an independent
blinded adjudication committee.
Results
Estimation of Renal Function
The baseline eGFR for the 4181 patients was non-normally
distributed around a median of 67.8 ml/min per 1.73 m2 (range,
9.7 to 149.2 ml/min per 1.73 m2). The eGFR at 1 mo was also
non-normally distributed with a median of 64.3 ml/min per
1.73m2 (range 7.42 to 119.1 ml/min per 1.73 m2) representing a
median change in eGFR of 3.5 ml/min per 1.73m2 over the
1-mo period. A total of 184 patients (4.9%) had an eGFR that
decreased by 25% from baseline over the 1-mo period.
Patients with WRF were more likely to have used diuretics
within 7 d of randomization, have clinical or echocardiographic
evidence of LV dysfunction, and have evidence of peripheral
arterial disease. Worsening renal function was not related to
differences in ACE inhibitor administration at discharge or the
addition of either ACE inhibitor or diuretic within the 30-d
period. In addition, the proportion of patients who had either a
diagnostic coronary angiogram or PCI for the index event was
not significantly greater in patients with WRF. Randomization
to the early intensive statin regimen did not alter the likelihood
of experiencing WRF (Tables 1 and 2).
Baseline serum CRP levels were significantly higher in the
proportion of patients who developed WRF. Even after adjust-
ment for other known predictors of WRF, the decrement in
eGFR was greater across increasing quartiles of baseline CRP
quartile.
Multivariable Predictors of Worsening Renal Function
Logistic regression was used to identify significant predictors
of early WRF in this patient population. On multivariate anal-
ysis, age per year increase (odds ratio [OR], 1.03; 95% confi-
dence interval [CI], 1.01, 1.05), female sex (OR, 2.37; 95% CI,
1.64, 3.42), baseline eGFR per milliliter per minute per 1.73 m2
increase (OR, 1.06; 95% CI, 1.05, 1.08) and the fourth quartile of
CRP (OR, 2.48; 95% CI, 1.49, 4.14) were significantly associated
with WRF after multivariable adjustment (Figure 1).
Worsening Renal Function and Cardiovascular Outcomes
Worsening renal function 1 mo after an admission for an ACS
was associated with a higher incidence of a subsequent com-
posite cardiovascular event (adjusted hazard ratio [HR], 1.59;
95% CI, 1.10, 2.30). Although the composite CV events were
more likely in the WRF group, only recurrent MI remained
significant after adjustment (HR, 1.68; 95% CI, 1.01, 2.79; Table
3; Figure 2). Other significant multivariate predictors of the
combined cardiovascular composite endpoint included a his-
tory of a previous MI (HR, 2.01; 95% CI, 1.61, 2.51), diabetes
(HR, 1.63; 95% CI, 1.3, 2.0) or hypertension (HR, 1.41; 95% CI,
1.1, 1.7), and increased age and a baseline CRP in the third (HR,
1.38; 95% CI, 1.04, 1.8) or fourth quartile (HR, 1.5; 95% CI, 1.13,
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2.0). The prognostic value of worsening renal function re-
mained significant even after multivariate adjustment, includ-
ing baseline renal function (HR, 1.37; 95% CI, 1.04, 1.8). The
analysis did not change when the definition of worsening renal
function was changed to an increase in serum creatinine 0.3
mg/dl. (unadjusted HR for the combined CV endpoint, 2.21
[95% CI, 1.58, 3.11]; adjusted HR, 1.81 [95% CI, 1.25, 2.62] for the
risk of a creatinine increase 0.3 mg/dl relative to those whose
creatinine changed 0.3 mg/dl).
Discussion
Impaired baseline renal function is a potent independent risk
factor for cardiovascular events across broad spectrums of pa-
tients (1–8). This study showed that a decline in renal function
over a 1-mo period was an independent predictor of a subse-
quent cardiovascular event after an ACS, even after adjustment
for baseline renal function. A high baseline level of serum CRP
was an important multivariate predictor of the development of
worsening renal function after an ACS.
Worsening renal function has been shown to have prognostic
significance in many acute settings, including acute heart fail-
ure (13,14) and in patients after cardiac surgery (10,11). The
prognostic role of worsening renal function in patients has been
described in patients after ST elevation MI (9), but less well
defined in a broad cohort of patients with an ACS. In addition,
these previous studies restricted the definition of acute kidney
injury to that which occurs while patients remain in hospital.
This was the first study to evaluate the prognostic impact of a
decline in renal function that occurred over a longer time frame
after the initial peri-infarct period.
Inherent to the discussion of the significance of worsening
renal function is the lack of a standardized definition of this
outcome. Many clinical studies have defined worsening renal
function as an increase in serum creatinine 0.3 mg/dl
Table 1. Baseline clinical characteristics of population based on an early decline in renal function (decline in GFR
of 25% over 1 mo)
Characteristic eGFR Decrease 25%(n  3611)
eGFR Decrease 25%
(n  184) P
Age (yr; mean  SD) 60.2 10.6 60.8 10.4 0.4
Female sex (%) 23.2 38.6 0.001
Diuretic use within 7 days (%) 22.7 32.1 0.01
Lytics (%) 21.7 22.8 0.7
Clinical or echo evidence LV
dysfunction (%) 11.2 16.9 0.02
Prior CV history
MI (%) 16.6 15.8 0.8
CABG (%) 4.0 3.8 0.9
Diagnostic cath before
Enrollment in Z (%) 54.9 59.8 0.2
Previous PCI (%) 4.3 5.4 0.5
PCI for index event (%) 42.1 43.7 0.7
PAD (%) 5.6 9.2 0.01
Cerebral vascular disease (%) 5.8 7.1 0.5
CHF 6 wk (%) 4.9 2.7 0.2
DM (%) 20.6 21.2 0.8
HTN (%) 49.4 56.5 0.06
Current smoking (%) 40.7 45.1 0.2
Qualifying event
STEMI (%) 39.7 44.6 0.2
Concomitant therapies at discharge
ASA (%) 96.7 94.6 0.1
 blocker (%) 83.5 80.4 0.3
ACE inhibitor (%) 57.9 62 0.3
Medications added b/w discharge and 30 days
Diuretics (%) 5.5 8.2 0.1
ACE inhibitor (%) 9.1 10.3 0.6
Randomized to intensive statin group (%) 51.2 47.8 0.4
LV, left ventricle; MI, myocardial infarction; CABG, coronary artery bypass grafting; PCI, percutaneous intervention; PAD,
peripheral artery disease; CHF, congestive heart failure; DM, diabetes mellitus; HTN, hypertension; STEMI, segment elevation
myocardial infarction.
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(12,21,22), a threshold that has been found in prior studies of
patients with heart failure to have the highest sensitivity (81%)
and specificity (62%) for predicting mortality. However, when
comparing the association of incremental rises in creatinine to
increased risk for a cardiovascular event, it has been suggested
that a particular threshold for worsening renal function may
not exist and that there is a continuous increase in risk with the
magnitude of the creatinine change (20). In addition, the pre-
cision of the creatinine determination and regression to the
mean may limit the value of small changes. In this study, a 25%
decline in eGFR was used to define a significant change in renal
function. This definition corresponds to the “risk” category in
the RIFLE (risk, injury, failure, loss, and end stage) classifica-
tion (22) and has been used in previous studies evaluating the
prognostic significance of an early decline in renal function (23).
A change in eGFR was chosen over a change in creatinine to
reflect the knowledge that eGFR is accepted as a better estimate
of kidney function. The accuracy of serum creatinine as a
marker of renal function is limited, because of nonlinear asso-
ciations with eGFR that vary with age, gender, race, and lean
body mass (23).
Worsening renal function occurred in 5% of this population
after an ACS event. Advanced age, female gender, and a base-
line CRP in the fourth quartile were significant independent
predictors of worsening renal function; however, a higher base-
line eGFR was also positively related to the development of
WRF. The relationship between higher baseline eGFR and WRF
may be a representation of regression toward the mean. Al-
Table 2. Baseline biochemical characteristics of population based on an early decline in renal function (decline in
GFR of 25% over 1 mo)
Characteristic eGFR Decrease 25%(n  3611)
eGFR Decrease 25%
(n  184) P
Baseline creatinine (mg/dl) (median, IQR) 1.1 (1.0, 1.2) 1.0 (0.8, 11) 0.001
Baseline eGFR (ml/min per 1.73 m2) (median,
IQR)
67.9 (58.8, 77.8) 78.7 (63.7, 79.8) 0.001
Mean change in creatinine 0.02 0.2 0.48 0.5 0.001
Mean change in eGFR 2.06 8.6 25.0 8.7 0.001
Chemistry
Total cholesterol (mg/dl) (median, IQR) 185 (74, 381) 181 (93, 276) 0.06
HDL (mg/dl) (median, IQR) 39 (33 45) 38 (33, 46) 0.8
LDL (median, IQR) 112 (29, 320) 109 (43, 206) 0.1
Triglycerides (median, IQR) 150 (116, 199) 142 (114, 194) 0.3
CRP (mg/dl) (median, IQR) 20 (7.6, 43.3) 31 (12.5 74.8) 0.001
Peak CK (ratio of the upper limit of normal) 6.2 112 3.6 4.3 0.3
Peak troponin (ratio of the upper limit of
normal)
267 2338 62.4 258 0.6
Serum creatinine in mg/dl may be converted to mol/L by multiplying by 88.4.
eGFR, estimated GFR; HDL, high-density lipoprotein; LDL, low-density lipoprotein; CRP, C reactive protein; CK, reatinine
kinase.
Figure 1. Multivariate predictors of worsening renal function
(decline in eGFR 25%) over a 1-mo period.
Figure 2. Kaplan-Meier estimates of the rate of death from any
cause and the cardiovascular composite (CV death, recurrent
MI, CHF, or stroke) endpoint according to a significant change
in estimated GFR over 1 mo (Log rank, P  0.001).
1814 Clinical Journal of the American Society of Nephrology Clin J Am Soc Nephrol 4: 1811–1817, 2009
though chronic kidney disease is associated with an increased
risk of acute kidney injury, the differences in the baseline eGFR
between these two groups may not have been clinically signif-
icant, because both groups would have been considered to have
mild chronic kidney disease based on their median eGFRs. It is
also possible that, in this patient population, there were other
stronger determinants of an early decline in renal function,
such as the presence of acute heart failure. Although there were
no significant differences in a history of heart failure (HF)
between groups who did and did not develop WRF; subjects
with WRF were more likely to have clinical or echocardio-
graphic evidence of LV dysfunction or diuretic use within 7 d
of admission. Serum levels of B-type natriuretic peptide have
been associated with the development of HF after an ACS (24).
As all patients in this study had measurements of serum CRP
done in the early phase of an acute coronary syndrome, their
baseline CRP levels were significantly elevated consistent with
the acute phase response. Despite these elevations, CRP levels
in the fourth quartile remained a significant independent pre-
dictor for the development of worsening renal function. In
addition, although measures of peak CK and troponin were
significantly different among the four quartiles of CRP, the
relationship was not linear, suggesting that the magnitude of
CRP during the index hospitalization was not purely a reflec-
tion of the extent of myocardial necrosis. More extensive myo-
cardial damage and HF may be associated with a decline in
renal function. Renal dysfunction at baseline is an important
independent risk factor in patients after an acute atherosclerotic
event. This has been shown with mild renal disease as assessed
by the eGFR (3,6).
Independent of baseline renal function, this study showed
that an early worsening of kidney function is an additional
predictor of cardiovascular risk. It is possible that an early
reduction in renal function is a marker for more advanced
disease or systemic inflammation, which may predispose the
patient to a recurrent cardiac event. However, the significance
of an early reduction in renal function was seen in addition and
independent of other traditional risk factors for recurrent car-
diovascular events.
There are some limitations to this analysis that should be
noted. Baseline serum creatinine was measured an average of
4.6 d after the initial ACS event and repeated 30 d later. The
variation in measurement may have affected the results
through transient changes in renal function. However, this
emphasizes the importance that a single measurement or a
transient change in renal function still has important prognostic
significance. Another important limitation is the fact that it is
not possible to differentiate the component of CRP related to
baseline inflammation versus that related to myocardial necro-
sis. Because extent of myocardial necrosis is a known prognos-
tic marker, this potentially confounds the relationship between
CRP and eGFR. However, the peak CK and troponin levels
were not significantly different in those with and without the
development of WRF. Although worsening renal function was
defined based on a clinically meaningful decrease in eGFR by
25% or greater, there is not a standardized definition of this
Table 3. Hazard ratios and Kaplan-Meier event rate estimates for combined cardiovascular outcomes according to
a significant decrease in GFR over 1 mo
Outcome eGFR Decrease 25%(n  3611)
eGFR Decrease 25%
(n  184)
Combined CV death/CHF/recurrent MI/stroke (%)
Event rate (N) 12.7 (435) 22 (38)
Unadjusted (95% CI) 1.0 1.86 (1.33, 2.59)
Adjusted (95% CI) 1.0 1.59 (1.10, 2.30)
CV death (%)
Event rate (N) 3.3 (111) 4.6 (8)
Unadjusted (95% CI) 1.0 1.46 (0.71, 2.99)
Adjusted (95% CI) 1.0 1.47 (0.70, 3.08)
CHF (%)
Event rate (N) 3.9 (135) 7.0 (12)
Unadjusted (95% CI) 1.0 1.80 (1.00, 3.26)
Adjusted (95% CI) 1.0 1.33 (0.70, 2.52)
Recurrent MI (%)
Event rate (N) 6.8 (234) 11.3 (20)
Unadjusted (95% CI) 1.0 1.78 (1.13, 2.81)
Adjusted (95% CI) 1.0 1.68 (1.01, 2.79)
CVA (%)
Event rate (N) 1.4 (47) 2.8 (4)
Unadjusted (95% CI) 1.0 1.74 (0.63, 4.83)
Adjusted (95% CI) 1.0 0.80 (0.19, 3.38)
eGFR, estimated GFR; CV, cardiovascular; CHF, congestive heart failure; MI, myocardial infarction; CVA, cerebral vascular
accident.
Clin J Am Soc Nephrol 4: 1811–1817, 2009 Change in GFR After an ACS 1815
outcome. Despite this, there was consistency in the results
when repeated using a change of creatinine 0.3 mg/dl as the
definition. There are also the limitations inherent to the mea-
surement of creatinine and estimated GFR calculation (23); this
may be particularly relevant given that follow-up body weight
was not recorded in this study. It is possible that small changes
in serum creatinine may have occurred secondary to a loss of
lean muscle mass after the acute illness.
An acute decline in renal function can occur after an ACS. In
the A-Z trial, this endpoint occurred in 5% of the enrolling
subjects within 1 mo of randomization. The etiology of this
decline is likely multifactorial; however, a high baseline CRP is
an independent predictor of a subsequent decrease in estimated
GFR. Our study provides support for the hypothesis that in-
flammation may be involved in renal dysfunction after an acute
cardiac injury. Further studies are needed to clarify the rela-
tionship between an early decline in eGFR, baseline CRP, and
extent of myocardial necrosis. An early decline in renal function
after ACS is an independent predictor of recurrent events,
independent of other traditional prognostic markers and base-
line renal function. This supports the routine measurement of
serum creatinine at follow-up visits.
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